Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in 2-Year extension trial

NCT ID NCT05916365

Completed Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who completed a previous year-long study could join this 2-year extension. The main goal was to see how many people stopped treatment due to side effects, and researchers also tracked how well the drug controlled eczema symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

  • Investigator Site 1

    Augsburg, 86150, Germany

  • Investigator Site 10

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Investigator Site 11

    Münster, North Rhine-Westphalia, 48149, Germany

  • Investigator Site 12

    Leipzig, Saxony, 04103, Germany

  • Investigator Site 13

    Gdansk, 80-462, Poland

  • Investigator Site 14

    Katowice, 40-600, Poland

  • Investigator Site 15

    Kielce, 25-155, Poland

  • Investigator Site 16

    Lublin, 20-081, Poland

  • Investigator Site 17

    Poznan, 60-214, Poland

  • Investigator Site 18

    Rzeszów, 35-055, Poland

  • Investigator Site 19

    Szczecin, 71-434, Poland

  • Investigator Site 2

    Berlin, 10789, Germany

  • Investigator Site 20

    Tarnów, 33-100, Poland

  • Investigator Site 21

    Warsaw, 01-142, Poland

  • Investigator Site 22

    Wroclaw, 50-566, Poland

  • Investigator Site 23

    Wroclaw, Lower Silesian Voivodeship, 51-503, Poland

  • Investigator Site 24

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Investigator Site 25

    Krakow, Lesser Poland Voivodeship, 31-559, Poland

  • Investigator Site 26

    Krakow, Lesser Poland Voivodeship, 30-033, Poland

  • Investigator Site 27

    Warsaw, Masovian Voivodeship, 02-625, Poland

  • Investigator Site 28

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Investigator Site 29

    Ossy, Silesian Voivodeship, 42-624, Poland

  • Investigator Site 3

    Berlin, 13055, Germany

  • Investigator Site 30

    Gdansk, Woj. Pomorskie, 80-344, Poland

  • Investigator Site 31

    Iwonicz-Zdrój, Podkarpackie Voivodeship, 38-440, Poland

  • Investigator Site 32

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Investigator Site 4

    Dresden, D-01307, Germany

  • Investigator Site 5

    Hamburg, 20144, Germany

  • Investigator Site 6

    Hamburg, 20537, Germany

  • Investigator Site 7

    Darmstadt, Hesse, 64283, Germany

  • Investigator Site 8

    Frankfurt am Main, Hesse, 60590, Germany

  • Investigator Site 9

    Osnabrück, Lower Saxony, 49074, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.